Claims for Patent: RE44733

Summary for Patent: RE44733

Title:	6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Abstract:	Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p--; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block. ##STR00001##
Inventor(s):	Zhang; Mingiang (Montreal, CA), Palin; Ronald (Banton, GB), Bennett; Jonathan (Edinburgh, GB)
Assignee:	Merck Sharp & Dohme B.V. (Haarlem, NL)
Application Number:	13/432,742
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE44733
Patent Claims:	1. A 6-mercapto-cyclodextrin derivative having the general formula I ##STR00025## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof; with the exclusion of 6-per-deoxy-6-per-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-per-deoxy-6-per-(2-hydroxyethylthio)-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(carboxymethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(carboxymethylthio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis((o-carboxyphenyl)thio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-.beta.-cyclodextrin and 6-per-deoxy-6-per-(2,3-dihydroxypropylthio)-.beta.-cyclodextrin. 2. The 6-mercapto-cyclodextrin derivative according to claim 1, wherein R, m and n are defined as in claim 1 and X is COOH or SO.sub.2OH; or a pharmaceutically acceptable salt thereof. 3. The 6-mercapto-cyclodextrin derivative according to claim 1, wherein m is 0; n is 8; R is (C.sub.1-6)alkylene or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; and X is COOH or SO.sub.2OH; or a pharmaceutically acceptable salt thereof. 4. A 6-mercapto-cyclodextrin derivative according to claim 1 selected from the group consisting of: 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(3-carboxypropyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(4-carboxyphenylmethyl)thio-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(2-carboxypropyl)thio-.gamma.-cyclodextrin; and 6-per-deoxy-6-per-(2-sulfoethyl)thio-.gamma.-cyclodextrin; or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical composition comprising a 6-mercapto-cyclodextrin derivative having the general formula I ##STR00026## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or a pharmaceutically acceptable salt thereof, with the exclusion of 6-per-deoxy-6-per-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(2-hydroxyethylthio)-.beta.-cyclodextrin; 6-per-deoxy-6-per-(2-hydroxyethylthio)-.gamma.-cyclodextrin; 6-per-deoxy-6-per-(carboxymethylthio)-.beta.-cyclodextrin; 6-mono-deoxy-6-mono-(carboxymethylthio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis((o-carboxyphenyl)thio)-.beta.-cyclodextrin; 6A,6B-dideoxy-6A,6B-bis(carboxymethylthiol)-.beta.-cyclodextrin and 6-per-deoxy-6-per-(2,3-dihydroxypropylthio)-.beta.-cyclodextrin, in admixture with pharmaceutically acceptable auxilliaries. 6. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) a 6-mercapto-cyclodextrin derivative according to the general formula I ##STR00027## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or a pharmaceutically acceptable salt thereof. 7. The kit according to claim 6, wherein the neuromuscular blocking agent is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine and suxamethonium. 8. The kit according to claim 6, wherein the neuromuscular blocking agent is rocuronium. 9. A method for reversal of drug-induced neuromuscular block in a patient, which comprises parenterally administering to said patient an effective amount of a 6-mercaptocyclodextrin derivative according to the general formula I ##STR00028## wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituted with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or a pharmaceutically acceptable salt thereof. .Iadd.10. The kit according to claim 6, wherein the neuromuscular blocking agent is vecuronium..Iaddend. .Iadd.11. 6-Per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof..Iaddend. .Iadd.12. 6-Per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt..Iaddend. .Iadd.13. A pharmaceutical composition comprising 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically suitable auxiliary..Iaddend. .Iadd.14. A pharmaceutical composition comprising 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt, and a pharmaceutically suitable auxiliary..Iaddend. .Iadd.15. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof..Iaddend. .Iadd.16. A kit for providing neuromuscular block and its reversal comprising (a) a neuromuscular blocking agent, and (b) 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt..Iaddend. .Iadd.17. The kit according to claim 15, wherein the neuromuscular blocking agent is selected from the group consisting of rocuronium, vecuronium, pancuronium, rapacuronium, mivacurium, (cis)atracurium, tubocurarine and suxamethonium..Iaddend. .Iadd.18. The kit according to claim 15, wherein the neuromuscular blocking agent is rocuronium..Iaddend. .Iadd.19. The kit according to claim 15, wherein the neuromuscular blocking agent is vecuronium..Iaddend. .Iadd.20. A method for reversal of drug-induced neuromuscular block in a subject, which comprises parenterally administering to said subject an effective amount of 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, or a pharmaceutically acceptable salt thereof..Iaddend. .Iadd.21. A method for reversal of drug-induced neuromuscular block in a subject, which comprises parenterally administering to said subject an effective amount of 6-per-deoxy-6-per-(2-carboxyethyl)thio-.gamma.-cyclodextrin, sodium salt..Iaddend.